RIGL
Rigel Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$48.67
+0.35%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 276.8M | 294.3M | 179.3M | 116.9M | 120.2M |
| Cost of Revenue | 23.8M | 19.6M | 18.6M | 7.1M | 1.7M |
| Gross Profit | 252.9M | 274.7M | 160.6M | 109.8M | 118.5M |
| Operating Expenses | |||||
| R&D Expense | 43.7M | 33.3M | 23.4M | 24.5M | 60.3M |
| SG&A Expense | 122.2M | 115.9M | 113.1M | 105.7M | 112.5M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | 1.3M |
| Total Operating Expenses | 165.9M | 149.2M | 136.4M | 130.3M | 174.0M |
| Cost and Expenses | 189.7M | 168.8M | 155.1M | 137.4M | 175.8M |
| Operating Income (EBIT) | 87.0M | 125.5M | 24.2M | (20.5M) | (55.5M) |
| Non-Operating | |||||
| Interest Income | 4.3M | 3.7M | 2.1M | 2.3M | 684.0K |
| Interest Expense | 5.8M | 7.3M | 7.9M | 6.9M | 3.7M |
| Net Interest Income | (1.5M) | (3.6M) | (5.8M) | (4.6M) | (3.0M) |
| Other Non-Op Income/Expense | (1.5M) | (3.6M) | (5.8M) | (4.6M) | (3.0M) |
| Non-Operating Income (excl Interest) | (4.3M) | (3.7M) | (2.1M) | (2.3M) | (684.0K) |
| EBT (Pre-Tax Income) | 85.6M | 121.8M | 18.4M | (25.1M) | (58.6M) |
| Income Tax Expense | (236.3M) | (245.2M) | 881.0K | — | — |
| Bottom Line | |||||
| Net Income | 321.9M | 367.0M | 17.5M | (25.1M) | (58.6M) |
| Earnings from Cont. Ops | 321.9M | 367.0M | 17.5M | (25.1M) | (58.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 321.9M | 367.0M | 17.5M | (25.1M) | (58.6M) |
| Per Share | |||||
| Basic EPS | $17.67 | $20.40 | $0.99 | ($1.44) | ($3.40) |
| Diluted EPS | $16.32 | $19.48 | $0.99 | ($1.44) | ($3.40) |
| Revenue Per Share | $14.93 | $16.36 | $10.20 | $6.72 | $6.97 |
| Shares | |||||
| Basic Shares Outstanding | 18.5M | 18.0M | 17.6M | 17.4M | 17.2M |
| Diluted Shares Outstanding | 19.6M | 18.8M | 17.7M | 17.4M | 17.2M |
| Profitability Metrics | |||||
| EBITDA | 94.0M | 131.6M | 28.5M | (17.0M) | (53.9M) |
| D&A | 2.6M | 2.4M | 2.2M | 1.2M | 998.0K |
| EBIT | 91.4M | 129.1M | 26.3M | (18.2M) | (54.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026